Meeting
2021 ASCO Annual Meeting
A single institution experience with droplet digital polymerase chain reaction (dd-PCR) liquid biopsy (LB) for therapeutic decision in advanced solid tumors.
Authors
Andre Marcio Murad
Personal. Oncologia de Precisao e Personalizada, Belo Horizonte, Brazil
Andre Marcio Murad , Juliana Garcia Carneiro , José Claudio Casali-da-Rocha
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3038)
DOI
10.1200/JCO.2021.39.15_suppl.3038
Abstract #
3038
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Characterization of diverse targetable ERBB2 alterations in 512,993 patients with solid tumors.
First Author: Dazhi Liu
Poster
2021 ASCO Annual Meeting
Comprehensive molecular profiling of advanced cancers in a real-world setting using an ultrasensitive amplicon-based next-generation sequencing (NGS) liquid biopsy assay.
First Author: Jonathan Poh
Poster
2020 ASCO Virtual Scientific Program
Therapeutic vulnerabilities among KRAS G12C mutant (mut) advanced cancers based on co-alteration (co-alt) patterns.
First Author: Maliha Nusrat
Poster
2019 ASCO Annual Meeting
The efficacy of immune checkpoint inhibitors and PD-L1 status in patients with advanced non-small cell lung cancer harboring oncogenic driver alterations: Immuno-oncology biomarker study in LC-SCRUM-Japan.
First Author: Kiyotaka Yoh